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Mechanisms of vascular damage in SSc—implications for vascular
treatment strategies
S. Guiducci1, O. Distler2, J. H. W. Distler3 and M. Matucci-Cerinic1
Vascular abnormalities are a major component of SSc, but little is known about the events or mechanisms that initiate vascular injury and
prevent its repair. In SSc, angiogenesis is incomplete or lacking despite the increased expression of a large array of pro-angiogenic factors
such as VEGF. Conflicting results have recently been published concerning the presence and role of vasculogenesis and circulating
endothelial progenitor cells in SSc. It remains to be established if these endothelial progenitor cells are a marker of endothelial disease or a
cause of insufficient vascular repair. Human mesenchymal stem cells (MSCs) may be an alternative source for endothelial progenitor cells,
and it has been observed that the angiogenic potential of endothelial-like MSCs is reduced. Other mechanisms of vascular damage include
oxidative stress and factors released from activated platelets. In addition, growth factors such as ET-1 and PDGF induce proliferation of
vascular smooth muscle cells resulting in intimal thickening. For the development of new therapeutic strategies, it is important to realize that
the different vascular pathologies—uncompensated loss of capillaries on one hand and vascular remodelling with a proliferative vasculopathy
on the other—might require different treatment approaches.
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Introduction
SSc is characterized by a complex array of clinical features
involving internal organs and the skin. A common pathogenetic
leitmotif to all these features is not only fibrosis due to excessive
collagen production, but is also the overall microvascular
involvement, in the early phases of the disease [1]. This dictates
the pace of the disease that progresses silently until the major
damage to the vessel wall is done. The modifications of the
microvasculature may be observed by nail-fold capillaroscopy [1]
and the progression of capillary deterioration, from giant
capillaries to architectural modification and desertification, can
be easily followed. Therefore, a major problem for the clinician is
modulation of the process leading to vessel modifications and the
capacity we may have to foster ‘regeneration’ of the damaged and
disappeared vessels. In this review, we will present the state-of-the-
art mechanisms of vascular damage in SSc and outline strategies
to develop novel vascular therapies for this disease.
Angiogenesis and vasculogenesis
In most adult organisms, endothelial cells (ECs) are quiescent with
turnover rates estimated to be in the order of years, with the
exception of the reproductive cycle in fertile females and in wound
healing or tissue regeneration [2]. Angiogenesis, the creation of
new blood vessels from pre-existing ones, mainly depends on the
activation, proliferation and migration of ECs, and is driven by
angiogenic stimuli that also induce proteolytic enzymes cleaving
extracellular matrix (ECM). The balance between pro-angiogenic
and anti-angiogenic factors tightly regulates angiogenesis [3]. This
event is highly complex and requires a dynamic, temporally and
spatially regulated interaction between ECs, soluble angio-
genic growth factors and ECM molecules. On one hand, EC
proliferation and new vessel formation is characteristic of several
diseases such as cancer and macular degeneration [2], while on the
other hand EC death is also a typical feature of diseases such as
atherosclerosis, allograft vasculopathy, heart failure, diabetic
retinopathy and SSc.
Vasculogenesis is defined as the formation of new vessels from
progenitor cells. Bone marrow-derived cells contribute to physio-
logical and pathological vascular remodelling throughout onto-
genesis and adult life. Following tissue ischaemia, progenitor cells
are mobilized from their bone marrow or peripheral niches into
the circulation, adhere at sites of vascular lesion and differentiate
into a variety of mature cell types according to their origin and the
local environment [4]. Impairment in this pathophysiological
process due to either low numbers of circulating progenitor cells
or dysfunctional progenitor cells, leads to inadequate vascular
repair. Vascular repair is a complex process that includes
mobilization, chemotaxis, adhesion, proliferation and differentia-
tion of progenitor cells. Although homing of progenitor cells into
bone marrow has been extensively studied [5], migration of
precursor cells into peripheral tissues and differentiation into
mature cells is poorly understood so far. The regenerative ability
of progenitor cells following organ injury is well established.
Progenitor cells promote structural and functional repair in
several organs such as the heart, liver, kidney or brain. For
instance, CD34þ cells have been described to be recruited to the
ischaemic myocardium, differentiating into cardiac and vascular
cells, and restoring cardiac function. Progenitor cells migrate to
sites of vascular injury and differentiate not only into an
endothelial phenotype (vascular repair), but also into vascular
smooth muscle cells or foam cells contributing, therefore, to
neointimal formation and eventually to vascular disease [6].
Moreover, Tanaka and colleagues [7] showed that bone marrow
cells contribute to neointimal hyperplasia after mechanical
vascular injuries. However, it is poorly understood as to which
factors influence the fate of progenitor cells in damaged tissues.
Vascular damage in SSc
In SSc pathogenesis, chronic inflammation plays a role in EC
ageing and damage. Vascular abnormalities are a major compo-
nent of SSc, but little is known about the events or mechanisms
that initiate vascular injury, prevent its repair and lead to loss
of angiogenesis [8]. Early stages of SSc are characterized by
an exaggerated angiogenic response, later followed by fibrosis.
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The earliest clinical symptoms of SSc relate to disturbances in the
peripheral vascular system [1] that may precede other manifesta-
tions by years. Fibrotic stages of SSc with the full-blown clinical
symptoms, often fail to exhibit prominent perivascular skin
infiltration, which can be found in the early inflammatory stage
of SSc. The initial events leading to vascular alterations are poorly
understood but are thought to involve EC injury. EC damage
impairs vascular supply, leading to tissue hypoxia, and promotes
inflammation and fibrosis. In response to damage, there is
enhanced expression of EC adhesion ligands that promote
inflammatory cell attachment, transmigration into the interstitial
space and tissue infiltration. The loss of viable ECs also leads to
loss of protective and vasodilating cytokines. In addition, vascular
smooth muscle cells proliferate in response to growth factors
resulting in intimal proliferation, matrix deposition in the vessel
wall and eventually complete occlusion of the vascular lumen
during the course of the disease. Thus, vascular disease is both
functional and structural: with reversible vasospasm as well as a
reduction in the capillary density followed by obliterative
vasculopathy. It is likely that prolonged EC perturbation and
activation may lead to dysfunction and irreversible loss of
integrity, with cell detachment and persistent tissue injury.
EC damage with apoptosis resulting in the loss of capillaries,
is considered as one of the earliest changes in the pathogenesis
of SSc [9].
SSc: a model for loss of angiogenesis
Despite the reduced capillary density, there is paradoxically no
sufficient angiogenic response in SSc. Tissue ischaemia leads
usually to the expression of angiogenic growth factors (e.g.
VEGF), which then initiate angiogenic sprouting by inducing
vasodilatation, proliferation and migration of ECs, and stabiliza-
tion of the lumina to form new vessels [10]. VEGF is the major
regulator of neovascularization. Plasma levels of VEGF are
elevated in SSc and this could stimulate angiogenesis [10].
Microvascular ECs (MVECs) from SSc patients showed
urokinase-type plasminogen activator-receptor (u-PAR) trunca-
tion between domains 1 and 2, a cleavage that is known to impair
u-PAR functions [11]. The u-PAR cleavage occurring in SSc
MVECs was associated with overexpression of MMP-12.
Overproduction of MMP-12 by SSc MVECs accounts for the
cleavage of u-PAR and the impairment of angiogenesis in vitro
and may contribute to reduced angiogenesis in SSc patients.
The role of vasculogenesis in SSc is less clear. Endothelial
progenitor cells might be recruited for vascular repair during
active disease [12]. However, conflicting results have been
published concerning the presence and role of circulating
endothelial progenitor cells in SSc [12]. Avouac et al. [13]
demonstrated increased circulating endothelial progenitor cell
levels in SSc, supporting their mobilization from bone marrow.
Furthermore, the subset of patients with digital vascular lesions
and high severity score displayed lower endothelial progenitor cell
counts, suggesting increased homing at this stage [13]. On the
other hand, there is data suggesting that vasculogenesis might be
impaired in SSc. This was demonstrated by the presence of a
substantially reduced number of bone marrow-derived circulating
endothelial precursors as compared with either healthy subjects or
patients affected by RA [14]. The lowest values of these immature
cells were observed in SSc patients with active fingertip ulcers,
suggesting that the inadequate recruitment of bone marrow-
derived circulating endothelial precursors might be related to an
impaired vascular repair mechanism [14]. It remains to be
established if these endothelial progenitor cells are a marker of
endothelial disease or a cause of insufficient vascular reparation.
Endothelial progenitor cells are important in vasculogenesis, and
may also be involved in other systemic features of inflammatory
rheumatic disorders [15]. Mesenchymal stem cells (MSCs) might
be another source of endothelial progenitor cells. MSCs show a
normal pattern of biological markers and functional properties
in SSc, but the angiogenic potential of endothelial-like MSCs is
reduced [16]. These cells, when seeded on Matrigel, have lower
ability to form capillary-like structures, giving rise to endothelial
networks that appeared incomplete and forming thinner vessels,
even after VEGF and stromal-derived factor (SDF-1) stimulation,
suggesting that endothelial repair may be affected in SSc starting
from the bone marrow.
Other mechanisms of vascular damage in SSc
Oxidative stress is associated with EC ageing, due to a progressive
reduction of the endogenous free radical scavengers over time.
Chronic exposure of ECs to radical oxygen species induces
morphological changes and impairment of cell–cell adhesion.
Oxidative stress also increases vascular endothelial permeability,
which is coupled with alterations in EC signal transduction. In
SSc, the peroxidation product diene-conjugates and antibodies
against oxidized low-density lipoproteins were found to be
significantly increased [17].
The release of von Willebrand factor (vWF) into the circulation
reflects the activity of the vascular disease in SSc. vWF released
from the vascular endothelium of patients with SSc is also found
in the perivascular and interstitial matrix. This suggests that the
local microvessels of the papillary layer of the skin are damaged in
SSc [18]. Most of the high molecular-weight vWF binds to the
subendothelial connective tissue. The high molecular-weight vWF
bound to subendothelial collagen fibres can form bridges between
subendothelial matrix and platelet gpIb and gpIIb/IIIa receptors.
Therefore, it contributes to platelet adhesion and aggregation, and
the formation of thrombosis. Thus, the local vascular damage and
the subsequent release of high molecular-weight vWF may
contribute to local pathogenic processes.
Platelets adhere to activated ECs and current evidence suggests
that platelets contribute to vascular remodelling. In fact, platelets
are the major storage and delivery vehicles for pro- and anti-
angiogenic growth factors including VEGF-A and thrombospon-
din (TSP), cytokines and chemokines, such as SDF-1. By
site-specific deployment of these factors, platelets orchestrate the
local angiogenic stimulus within a tissue and direct the recruitment
and differentiation of circulating bone marrow-derived cells.
These insights have profound clinical implications; activation of
PDGFs or their receptors may be an effective strategy to promote
capillary growth.
ET-1, predominantly synthesized by ECs and smooth muscle
cells, is the strongest vasoconstrictor known, enhances mitogenesis
and induces ECM formation. The capacity to regulate growth of
mesenchymal cells, to induce collagen and fibronectin production
and cell migration, make ET one of the main regulators of ECM
synthesis and vascular and interstitial remodelling. In SSc,
increased plasma ET-1 levels are involved in enhanced vasocon-
striction, vascular EC proliferation, smooth muscle hypertrophy
and irreversible vascular remodelling [19].
Conclusion and consequences for therapeutic approaches
The extensive vascular damage and loss of angiogenesis makes SSc
an ideal model to study novel therapeutic strategies for vascular
regeneration. It has been convincingly shown that different
pro-angiogenic stimuli are present in SSc that do not elicit an
appropriate angiogenic response. Still, the mechanism of this lack
of response and loss of angiogenesis are poorly understood.
However, a number of key factors and additional mechanisms
have been identified in recent years that may significantly
contribute to the vascular damage in SSc.
For the development of new therapeutic strategies, it is
important to realize that there are parallel vascular pathologies
that might require additive therapeutic approaches. These
vascular pathologies consist mainly of vasoconstriction driven
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by an imbalance of vasoconstrictive/vasodilatory factors, vascular
damage and loss of capillaries not compensated by new vessel
formation, and a proliferative vasculopathy with prominent
intimal proliferation further leading to an impaired blood flow
in tissues.
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Rheumatology key messages
 Angiogenesis is impaired in SSc despite the up-regulation of a
large array of pro-angiogenic factors.
 The role of vasculogenesis in SSc is controversial and needs to be
addressed by further studies.
 Other mechanisms of vascular damage in SSc include oxidative
stress and platelet activation.
 Loss of capillaries without compensation by angiogenesis/
vasculogenesis and a proliferative vasculopathy with intimal
proliferation, are the main vascular features in SSc.
 Novel therapeutic approaches should address both of these main
vascular pathologies in SSc.
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